BOSTON, March 31, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish fourth quarter and fiscal year 2025 financial results at 6:00 am ET on Thursday, May 8, 2025. The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am ET on May 8, 2025. The call can be accessed via teleconference at: Q4 2025 Haemonetics Corporation Earnings Conference Call. Once registration is completed, participants will rec ...

Haemonetics Corporation’s (HAE) impressive Hospital business recovery is poised to drive growth in the upcoming quarters. The robust uptake of the NexSys PCS system bodes well for its long-term growth. Strong financial stability also buoys optimism. Meanwhile, a dull macroeconomic scenario and unfavorable foreign exchange remain concerns for HAE’s operations. In the past year, this Zacks Rank #3 (Hold) company’s shares have lost 14.5% against the industry and the S&P 500 composite’s growth of 9% and 10%, re ...

Frank Chan joins Haemonetics as Executive Vice President, Chief Operating Officer; Roy Galvin named Executive Vice President, Chief Commercial OfficerBOSTON, March 3, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, today announced updates to its Executive Leadership team. Frank Chan, Ph.D. will join Haemonetics as Executive Vice President, Chief Operating Officer on April 7, 202 ...

BOSTON, Feb. 24, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, President and CEO, will participate in a fireside chat with investors at the Raymond James 46th Annual Institutional Investors Conference on Tuesday, March 4, 2025 at 2:50 p.m. ET. The public may access a live webcast of the fireside chat at Haemonetics' Investor Relations website or at the following link: https://wsw.com/webcast/rj131/hae/1437678. A replay of the recorded webcast will become accessible 12 ...

TAKHZYRO Solution for Injection in 2 mL Pre-Filled Pen is Now Approved to Facilitate Subcutaneous Administration in Adolescent (Aged 12 Years and Above) and Adult Patients with HAE.1 The Pre-Filled Pen Option is Designed to Allow for An Individualized Treatment Approach for Adolescent and Adult HAE Patients. In the EU, TAKHZYRO is Approved for Routine Prevention of Recurrent HAE Attacks in Patients Aged 2 Years and Older.1ZURICH, Feb. 24, 2025 /PRNewswire/ -- Takeda (TSE: 4502) (NYSE: TAK) announced today ...

ANDEMBRY® is a first-in-class monoclonal antibody treatment that inhibits activated Factor XII (FXIIa), the initiating factor in the HAE pathway, and offers the first pre-filled pen presentation enabling once-monthly subcutaneous administration The approval is based on the results of the international pivotal Phase 3 VANGUARD trial, which included HAE patients from Japan CSL is dedicated to improving the lives of those with HAE – a community that we have proudly supported for more than 40 yearsTOKYO, Feb. ...

Core Insights - Astria Therapeutics (NASDAQ: ATXS) is highlighted as having an attractive risk-reward profile that the market may be underestimating [1] - The company has entered Phase 3 trials for its lead product targeting hereditary angioedema, indicating significant progress in its development pipeline [1] Company Analysis - Astria Therapeutics operates in the small-cap biotech sector, which is known for its volatility but also potential for high returns [1] - The focus on high-growth companies and disruptive technologies suggests a strategic positioning towards sectors with exponential expansion potential [1] Investment Perspective - The analysis emphasizes a mix of fundamental analysis and future trend prediction as a method for evaluating investment opportunities in innovative companies [1]

Haemonetics Corporation (HAE) delivered third-quarter fiscal 2025 adjusted earnings per share (EPS) of $1.19, which rose 14.4% year over year. The bottom line was on par with the Zacks Consensus Estimate. Find the latest EPS estimates and surprises on Zacks Earnings Calendar.On a GAAP basis, EPS was 74 cents compared with 61 cents in the prior-year quarter.Following the earnings announcement, shares of HAE rose 0.02% in after-market trading yesterday. HAE’s Q3 RevenuesRevenues increased 2.7% to $348.5 milli ...

Haemonetics Corporation (NYSE:HAE) Q3 2025 Earnings Conference Call February 6, 2025 8:30 AM ET Company Participants Olga Guyette - Vice President, Investor Relations and Treasury Christopher Simon - President and Chief Executive Officer James D'Arecca - EVP and Chief Financial Officer Conference Call Participants Anthony Petrone - Mizuho Financial Group Marie Thibault - BTIG David Turkaly - Citizens JMP Andrew Cooper - Raymond James Mike Matson - Needham & Company Craig Bijou - Bank of America Securities M ...

Haemonetics (HAE) reported $348.54 million in revenue for the quarter ended December 2024, representing a year-over-year increase of 3.7%. EPS of $1.19 for the same period compares to $1.04 a year ago.The reported revenue represents a surprise of -1.30% over the Zacks Consensus Estimate of $353.15 million. With the consensus EPS estimate being $1.19, the company has not delivered EPS surprise.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expecta ...